257 results about "Immunogen" patented technology

The invention relates to germline-targeting designs, stabilization designs, and / or combinations thereof, of proteins designed with modified surfaces helpful for immunization regimens, other protein modifications and / or development of nanoparticles, methods of making and using the same, and to (a) germline-targeting priming or boosting / shepherding immunogens to initiate or guide maturation of VRC01-class responses (b) PCT64 / PG9-germline-targeting designs (c) BG18-germline-targeting designs or boosting / shepherding immunogens to initiate or guide maturation of BG18-like responses, and / or (d) trimer stabilization and presentation in a membrane-bound format.

The invention relates to the technical field of biological medicines, and discloses a PD-L1 K263 acetylation modified antibody, which is prepared from an immunogen containing a sequence as shown in SEQ ID NO.1. The PD-L1 K263 acetylation modified antibody is a PD-L1 K263 acetylation modified antibody. The invention also discloses a preparation method of the PD-L1 K263 acetylation modified antibody. The preparation method comprises the following steps: designing and synthesizing a polypeptide antigen, preparing an immunogen, immunizing animals, purifying the antibody and evaluating serum titer. The antibody provided by the invention can accurately recognize and combine with the PD-L1 protein subjected to K263 acetylation modification in the breast cancer, provides a specific tool for qualitative and quantitative detection of K263Ac-PD-L1 in the breast cancer, and provides a reliable molecular marker detection means for evaluating the curative effect of anti-PD-1 / PD-L1 immunotherapy; therefore, a biological preparation with specificity and practicability and a technical support are provided for accurate diagnosis, targeted therapy and curative effect monitoring of breast cancer.

The invention provides a Garlu virus attenuated strain and application thereof, and relates to the field of virology and biological medicine. According to the invention, the screened Garlu virus attenuated strain is a natural attenuated strain derived from a tick sample, can grow in Vero cells, has the titer of more than or equal to 107 TCID50 / mL, does not have clinical pathogenicity to an immunodeficient host, and is safe; after the attenuated strain is used as an immunogen for pre-intervention, infection of a lethal virus strain can be avoided, the survival rate is increased to 100%, adverse effects on growth and life of experimental animals are avoided, particularly, a host can be stimulated to generate humoral immunity and cellular immunity at the same time, and the survival rate of the experimental animals is improved. And moreover, broad-spectrum cross-protection efficacy can be generated on Bandavirus lethal virus strains, and a foundation is laid for improvement of research on Bandavirus live vaccines such as the Colu virus and the like.

The invention discloses a preparation method and application of a cat main allergen FEL-1 nano antibody FEL-1-Nb, and relates to the technical field of antibody preparation, and the preparation method comprises the following steps: preparing an immunogen; animal immunization and library construction; constructing and panning a phage display library; screening and identifying positive clone; and expression and purification of the nano antibody: cloning the positively cloned VHH gene to an expression vector such as a pET series, transforming an expression strain such as escherichia coli BL21 (DE3), carrying out IPTG induced expression, and purifying through an inclusion body purification method to obtain a high-purity nano antibody protein. The nano antibody FEL-1-Nb provided by the invention can be specifically bound with a cat main allergen FEL-1 protein, the unique amino acid sequence of the nano antibody FEL-1-Nb is shown as SEQIDNO: 1, high-affinity binding with the FEL-1 protein is ensured, the positive clone binding rate is high through phage display panning and ELISA verification, the phage recovery rate after the third round of panning is increased by more than 1000 times compared with the first round of panning, and the positive clone binding rate is higher than that of the first round of panning. Therefore, the nano antibody has excellent targeted recognition capability.

The invention relates to molecular glue for forming fimbriae related protein based on SpaA isopeptide bonds of Vinci bacteria. The invention also relates to a nanoparticle vaccine composition formed by the molecular glue, and the immunogen is covalently displayed on the surface of the nanoparticle by the molecular glue.

The application discloses camel-derived nanobodies of feline calicivirus and application thereof, and belongs to the field of biological medicine. The application takes feline calicivirus as an immunogen, and through steps of immunizing a camel, constructing a library, enriching sequencing and the like, two nanobodies VHH-V14 and VHH-V29 are screened, and the amino acid sequences of the two nanobodies are shown as SEQ ID NO. 1-2. Experimental results show that the nanobodies VHH-V14 and VHH-V29 are nanobodies with outstanding neutralization activity to feline calicivirus, and the IC 50 of the two nanobodies is 0.6536 mg / mL and 0.6931 mg / mL respectively, and the two nanobodies have good inhibiting effect on feline calicivirus. The application provides new biological materials for prevention and treatment of feline calicivirus infection, and provides new design theory and technical support for antibody treatment strategy of feline calicivirus, and has outstanding significance for clinical treatment of feline calicivirus infection.

The invention discloses an African swine fever mRNA vaccine composition capable of synergistically activating and enhancing humoral immunity and cellular immunity and application of the African swine fever mRNA vaccine composition, and belongs to the technical field of biological medicines. Specifically, a plurality of key antigen proteins of the African swine fever virus are used as target spots and are connected in series through connexons to form single-chain mRNA, so that multiple immunogens can be translated from the same transcript, and multiple antibodies are induced to be generated at the same time; a conservative recombinant T cell immunogen capable of activating cellular immune response is introduced, so that the cellular immune response can be enhanced, the ADE risk can be reduced, and the cross protection capability can also be improved; in addition, a molecular adjuvant IL-12 is added into the mRNA vaccine to enhance the immune response of the African swine fever vaccine, so that stronger immune protection efficacy is induced.

The present application relates to the technical field of antibodies, in particular to a monoclonal antibody specifically targeting human SLC19A1 and application thereof.The present application provides a monoclonal antibody specifically targeting human SLC19A1 and application thereof.The present application obtains human SLC19A1 protein by expression and purification through a eukaryotic expression system; then uses the obtained SLC19A1 protein as an immunogen to immunize mice to generate antibodies; finally, a monoclonal antibody specifically recognizing and combining SLC19A1 protein is obtained through flow enrichment and screening, and the epitope recognized and combined by the antibody is identified.It is verified that the monoclonal antibody provided by the present application can specifically recognize and combine the amino acid residues of human SLC19A1 protein, has high affinity, can be used as a molecular tool for detection of SLC19A1 protein, has high sensitivity and specificity, and has application advantages in detection of human SLC19A1 protein.

The present application provides a CD4 helper T cell epitope fusion peptide, its encoding nucleic acid and an immune composition comprising the same. The epitope fusion peptide comprises a cytomegalovirus epitope. The epitope fusion peptide provided by the present application can greatly improve the cellular immune response level of the target immunogen, especially a weak immunogen, and is an effective means to overcome the immune system's immune tolerance to antigens, especially tumor antigens or infection-related antigens, and is suitable for efficiently enhancing the efficacy of vaccines.

The use of anti-HPV immunogens and nucleic acid molecules encoding them for the treatment and prevention of RRP is disclosed.SOLUTION: Pharmaceutical compositions, recombinant vaccines comprising the DNA plasmids, and live attenuated vaccines are disclosed, as well as methods of inducing an immune response to treat or prevent RRP.SELECTED DRAWING: Figure 1

The invention discloses a Nipah virus F protein monoclonal antibody and application thereof, the antibody comprises an antibody 2D12 and an antibody 3B10, and the Nipah virus F protein monoclonal antibody is prepared from Nipah virus F protein immunogen. The specific anti-Nipah virus F protein monoclonal antibody pair is prepared and detected, the monoclonal antibody pair can be specifically combined with the Nipah virus F protein, is high in titer and good in affinity and has neutralizing activity, and meanwhile, the detection kit prepared on the basis of the antibody pair can effectively carry out Nipah virus detection; and technical support can be provided for treatment, epidemiological monitoring and diagnosis of Nipah virus infection.

The application discloses a kind of rice mycotic acid hapten and antigen preparation application, it is related to antigen preparation technical field, introduce sulfydryl in the 2 of rice mycotic acid, and obtain rice mycotic acid antigen by coupling with protein through connecting arm, rice mycotic acid hapten and antigen preparation application include the following specific flow: S1, the synthesis of rice mycotic acid hapten;S2, the preparation of rice mycotic acid immunogen;S3, the preparation of rice mycotic acid coating original;S4, the preparation of rice mycotic acid monoclonal antibody;S5, the preparation of rice mycotic acid immunofluorescence detection card;S6, rice mycotic acid detection in food;S7, detection limit experiment;S8, false positive rate, false negative rate experiment.The rice mycotic acid hapten retains the structural characteristics of rice mycotic acid, better exposes rice mycotic acid structural characteristics, improves the immunity and immune recognition ability of antigen, lays foundation for preparing specific, high sensitivity antibody, and improves its rapid detection ability.

The present invention is drawn to new oral live canine parainfluenza virus vaccines and related multivalent vaccines. Methods of using the vaccine alone or in combination with one or more other protective immunogens in multivalent vaccines are also provided.

In certain aspects the invention provides HIV-1 immunogens, including HIV-1 envelopes with optimized V2 loop for antibody induction.

The present invention relates to glycosylate HIV timer nanoparticles fused to self-assembling ferritin proteins which may be utilized as immunogens to enhance trafficking to lymph nodes and germinal centers and to heighten immune responses.

The invention relates to the technical field related to immunological detection, in particular to a mouse anti-porcine epidemic diarrhea virus monoclonal antibody, an immunogen and application thereof. The amino acid sequences of complementary determining regions CDR1, CDR2 and CDR3 of a heavy chain variable region of the monoclonal antibody or the antigen binding fragment of the monoclonal antibody are respectively as follows: GFSLSTSGVV, RIDPSDSYT and ARDREKSDNSGYFDY, and the amino acid sequences of complementary determining regions CDR1, CDR2 and CDR3 of a light chain variable region of the monoclonal antibody or the antigen binding fragment of the monoclonal antibody are respectively as follows: RASKSISKYLA, EASSLES and LQHTPKKNK. The monoclonal antibody can be specifically combined with nucleocapsid proteins (N proteins) of all subtypes of the porcine epidemic diarrhea virus, and a porcine epidemic diarrhea virus detection kit prepared from the monoclonal antibody has the advantages of high sensitivity, strong specificity, wide detection range, short detection time and the like.

The application belongs to the field of marine biotechnology, and specifically discloses a preparation method of a long oyster insulin-like peptide receptor (ILPR) polyclonal antibody and application thereof. The method is characterized by the following steps: specific antigen epitopes of the long oyster ILPR protein are screened through bioinformatics analysis, a pET32a-ILPR recombinant plasmid is constructed and induced to express in Escherichia coli; the purified recombinant protein is used as an immunogen to immunize New Zealand white rabbits, and rabbit antisera are collected after four times of booster immunization; specific polyclonal antibodies are purified by using antigen affinity chromatography technology, and can specifically recognize the ILPR protein in long oyster tissues. The antibody prepared by the application has high specificity and sensitivity, and provides an important biological tool for studying the insulin signal transduction pathway, growth regulation and energy metabolism mechanism of long oysters.

The application provides a monoclonal antibody against a TMED10 protein and an application thereof, and belongs to the technical field of biotechnology and the medical field of tumors; the application develops a monoclonal antibody against a TMED10 protein by taking a TMED10 recombinant protein as an immunogen; a light chain variable region amino acid sequence of the monoclonal antibody is shown in SEQ ID No: 3, and a heavy chain variable region amino acid sequence is shown in SEQ ID No: 4; a titer of the monoclonal antibody reaches 1x10 5 The monoclonal antibody has the characteristics of high specificity and high affinity, can be combined with the TMED10 protein specifically, can be used for immunological detection of cells, has a broad market prospect, can be used for preparing an immunological detection tool, and has important significance for further research and development of biological diagnosis and therapeutic drugs taking the TMED10 as a target and the like.

Disclosed herein are receptor binding domain (RBD) SARS-CoV-2 immunogens, engineered nanoparticle vaccines comprising receptor binding domain (RBD) SARS-CoV-2 immunogens and methods of use thereof for SARS- CoV-2 vaccines.

The invention relates to an application of a cerium oxide nano-material in a vaccine adjuvant and / or a vaccine inactivator, in particular to a vaccine, when the cerium oxide nano-material is the vaccine adjuvant, the vaccine comprises the vaccine adjuvant and an immunogen; or when the cerium oxide nano material is a vaccine inactivating agent, the vaccine is a composite vaccine, the composite vaccine comprises the vaccine inactivating agent and a virus, and the virus is embedded in the cerium oxide nano material; the preparation method of the composite vaccine comprises the step of mineralizing and inactivating viruses by using a vaccine inactivator, wherein the vaccine inactivator is cerium salt. The cerium oxide can be used as a vaccine adjuvant and also can be used as a virus inactivator. The maturation of dendritic cells and macrophages can be promoted by means of regulating the level of active oxygen in immune cells and the like, and the antigen presentation efficiency is improved, so that the vaccine-induced body fluid and cellular immune response is enhanced; meanwhile, cerium salt can directly act on virus surface protein for mineralization, efficient and safe virus inactivation is achieved, and preparation of inactivated vaccines is facilitated.

The present invention provides anti-B7H3 antibodies and their application thereof A group of murine anti-B7H3 monoclonal antibodies are prepared by hybridoma technology, using recombinant B7H3 protein as immunogen. Human-murine chimeric antibodies generated from the aforementioned murine anti-B7H3 hybridomas are capable of specifically binding to recombinant B7H3 protein and membrane-bound B7H3 on tumor cell lines. The derived B7H3 scFv-CD3ε-engineered T cells exhibit a significant cytotoxic effect on B7H3-positive tumor cell lines. Therefore, the anti-B7H3 antibodies and B7H3 scFv-CD3ε-engineered T cells have great application prospects in treating or ameliorating B7H3-associated diseases.

The invention provides application of M1 protein related substances in preparation of medicines for treating diseases caused by avian influenza viruses. The application is any one of the following applications: application of Y1 in preparation of medicines for preventing and / or treating diseases caused by avian influenza viruses or avian influenza virus infection; the Y2 is applied to preparation of an avian influenza virus inhibitor; the invention discloses application of Y3 in inhibition of avian influenza virus replication. After a mouse is immunized by the M1 recombinant protein, immune factors related to T cells are increased, secretion of proinflammatory factors is reduced, preparation is made for protecting a body from virus attack, and the M1 recombinant protein is also an expression for laterally improving the immunity of a host. The M1 protein has a good immune effect as an immunogen. The invention has application value in treatment of avian influenza virus and similar viruses.

The invention belongs to the technical field of biology, and discloses a monoclonal antibody capable of simultaneously recognizing multiple pedigree of porcine reproductive and respiratory syndrome virus GP5 protein. The invention discloses a recombinant protein. The recombinant protein is formed by repeatedly connecting two short peptides in series. The GP5 protein is a basis for dividing a PRRSV pedigree, the GP5 protein is taken as a research object, two regions with relatively strong immunogenicity on amino acid of the GP5 protein are repeatedly connected in series, and the two regions are further connected in series with a tag sequence or a Foldon oligopeptide to obtain a recombinant protein. The recombinant protein is used as an immunogen, and a monoclonal antibody capable of simultaneously identifying GP5 proteins of a plurality of pedigree (including pedigree 1, pedigree 3, pedigree 5 and pedigree 8) of PRRSV is prepared and screened.

The application discloses a recombinant FCV antigen and a construction method and application thereof. The construction method of the recombinant FCV antigen comprises the following steps: fusing a T cell epitope coding sequence of a non-structural protein NS7 of FCV and a coding sequence of a SpyTag peptide segment through a coding sequence of a linker, then cloning into a baculovirus transfer vector to obtain a recombinant plasmid, and finally integrating the T cell epitope coding sequence into Bacmid through Tn7 transposition to finally obtain the recombinant FCV antigen. The application selects NS7 as a core immunogen, guides the immune system to produce a high cellular immune response, and thus makes up for the deficiency of an existing vaccine in clearing intracellular viruses; meanwhile, a specific T cell epitope is selected in the sequence of NS7 as an immunogen, which can avoid the immunological escape caused by the variation degree of antigens among different strains and virus antigen drift, and thus provides broader protection.

Provided herein are vaccines against RSV. In some embodiments, the vaccine comprises an mRNA encoding a stabilized pre-fusion RSV F protein immunogen linked to a dioxotetrahydropteridine synthase based scaffold.

The invention relates to preparation of a cyclic adenosine monophosphate (cAMP) detection kit by using a chemiluminescence immunoassay technology. Cyclic adenosine monophosphate is an important second messenger for cell signal transduction and has wide physiological functions. Cyclic adenosine monophosphate is small in molecular weight and poor in immunogenicity, so that when a corresponding antibody is prepared, a proper derivative site needs to be selected firstly, and a derived hapten is coupled with a specific macromolecular carrier to prepare a complete antigen. According to the invention, the antibody with good specificity and strong affinity is successfully prepared by designing and transforming the hapten. The invention mainly relates to design and synthesis of a cyclic adenosine monophosphate hapten, preparation of a cyclic adenosine monophosphate complete antigen and an anti-cyclic adenosine monophosphate antibody, a method for measuring the concentration of cyclic adenosine monophosphate, and composition and components of a reagent. The design and synthesis of the hapten mainly comprise design and chemical synthesis of a cyclic adenylate derivative. The cyclic adenylic acid derivative disclosed by the invention has a structure as shown in a formula (I) which is described in the specification.

Compositions, kits, and systems containing tolythiazine haptens, immunogens, and / or protein conjugates are disclosed. Methods of producing and using the tolythiazine haptens, immunogens, and conjugates are also disclosed.

The invention relates to a preparation method of a cyclic guanylic acid (Guanosine 3 ', 5'-cyclic guanylic acid, cGMP) detection kit based on a chemiluminescence immunoassay technology, and particularly relates to a preparation method of a cyclic guanylic acid (Guanosine 3 ', 5'-cyclic guanylic acid, cGMP) detection kit based on a chemiluminescence immunoassay technology. Cyclic guanylate is small in molecular weight and poor in immunogenicity. When a corresponding antibody is prepared, a proper isomer and a derivative site need to be selected firstly, and a derivative hapten is coupled with a specific macromolecular carrier to prepare a complete antigen. According to the invention, the antibody with good specificity and strong affinity is successfully prepared by designing and transforming the hapten. The invention mainly relates to design and synthesis of a cyclic guanylic acid hapten, a cyclic guanylic acid complete antigen, preparation of an anti-cyclic guanylic acid antibody, a method for measuring the concentration of cyclic guanylic acid, and composition and components of a reagent. The design and synthesis of the hapten mainly comprise design and chemical synthesis of a cyclic guanylate derivative. The cyclic guanylate derivative disclosed by the invention has a structure as shown in a formula (I) which is described in the specification.